glimepiride has been researched along with Chronic Disease in 4 studies
glimepiride: structure given in first source
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6." | 9.22 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)." | 8.31 | Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023) |
| "A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6." | 5.22 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)." | 4.31 | Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaguchi, S | 1 |
| Shimabukuro, M | 1 |
| Tanaka, A | 2 |
| Imai, T | 1 |
| Hiramitsu, S | 1 |
| Takahashi, N | 1 |
| Kadokami, T | 1 |
| Ajioka, M | 1 |
| Suzuki, M | 2 |
| Node, K | 2 |
| Inoue, T | 1 |
| Kitakaze, M | 1 |
| Oyama, J | 1 |
| Sata, M | 1 |
| Taguchi, I | 1 |
| Shimizu, W | 1 |
| Watada, H | 1 |
| Tomiyama, H | 1 |
| Ako, J | 1 |
| Sakata, Y | 1 |
| Anzai, T | 1 |
| Uematsu, M | 1 |
| Eguchi, K | 1 |
| Yamashina, A | 1 |
| Saito, Y | 1 |
| Sato, Y | 1 |
| Ueda, S | 1 |
| Murohara, T | 1 |
| Matsumoto, K | 1 |
| Sera, Y | 1 |
| Abe, Y | 1 |
| Tominaga, T | 1 |
| Yeki, Y | 1 |
| Miyake, S | 1 |
| Bhattacharya, SK | 1 |
| Shastri, S | 1 |
| Mahajan, P | 1 |
| Madhu, SV | 1 |
| Tripathi, AK | 1 |
| Rauniar, GP | 1 |
| Das, BP | 1 |
| Paudel, KR | 1 |
1 trial available for glimepiride and Chronic Disease
| Article | Year |
|---|---|
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; | 2016 |
3 other studies available for glimepiride and Chronic Disease
| Article | Year |
|---|---|
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperinsulinism; H | 2023 |
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ | 2004 |
Polymorphonuclear leukocyte function in type-2 diabetes mellitus patients and its correlation with glycaemic control.
Topics: Adult; Aged; Blood Glucose; Chronic Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Fema | 2007 |